Magnetar Financial LLC Sells 8,572 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Magnetar Financial LLC lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 38.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 13,749 shares of the company’s stock after selling 8,572 shares during the period. Magnetar Financial LLC’s holdings in Cellebrite DI were worth $303,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CLBT. FMR LLC lifted its stake in Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after acquiring an additional 3,239,307 shares during the period. True Wind Capital Management L.P. lifted its stake in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after acquiring an additional 2,130,386 shares during the period. Principal Financial Group Inc. bought a new position in Cellebrite DI during the 3rd quarter valued at about $23,402,000. Lord Abbett & CO. LLC bought a new position in Cellebrite DI during the 3rd quarter valued at about $11,523,000. Finally, Summit Partners Public Asset Management LLC bought a new position in shares of Cellebrite DI in the 3rd quarter worth approximately $9,274,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a report on Monday, March 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI presently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $19.23 on Friday. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The company has a market capitalization of $4.61 billion, a P/E ratio of -13.83, a P/E/G ratio of 4.27 and a beta of 1.52. The firm’s 50 day simple moving average is $21.12 and its two-hundred day simple moving average is $19.78.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.